A Comparison of Attitudes Toward Cognitive Enhancement and Legalized Doping in Sport in a Community Sample of Australian Adults

AJOB Primary Research

Volumn 3, Issue 4, 2012, Pages 81-86

  Partridge, Brad ^a   Lucke, Jayne ^a   Hall, Wayne ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

cognitive enhancement; doping; methylphenidate; neuroenhancement; performance enhancing drugs; public attitudes; public opinion

Indexed keywords

EID: 84868697602     PISSN: 21507716     EISSN: 21507724     Source Type: Journal    
DOI: 10.1080/21507716.2012.720639     Document Type: Article

References (17)

1. Cakic, V. 2009. Smart drugs for cognitive enhancement: Ethical and pragmatic considerations in the era of cosmetic neurology. Journal of Medical Ethics, 35: 611-615.
2. Engelberg, T., Moston, S. and Skinner, J. 2012. Public perception of sport anti-doping policy in Australia. Drugs: Education, Prevention, and Policy, 19: 84-87.
3. Franke, A. G., Bonertz, C.Christmann, M. 2011. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry, 44: 60-66.
4. Greely, H., Sahakian, B.Harris, J. 2008. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456: 702-705.
5. Hoberman, J. 2005. Testosterone dreams: Rejuvenation, aphrodisiac, doping., Berkeley: University of California Press.
6. Kayser, B., Mauron, A. and Miah, A. 2005. Viewpoint: Legalisation of performance-enhancing drugs. Lancet, 366: S21
7. Kayser, B. and Smith, A. C. T. 2008. Globalisation of anti-doping: The reverse side of the medal. British Medical Journal (Clinical Research), 337(7661): 85-87.
8. Knorr Cetina, K. 2005. The rise of a culture of life. EMBO Reports, 6: S76-S80.
9. Larriviere, D., Williams, M. A.Rizzo, M. 2009. Responding to requests from adult patients for neuroenhancements. Guidance of the Ethics, Law and Humanities Committee. Neurology, 73: 1406-1412.
10. Lucke, J. C. 2012. Empirical research on attitudes toward cognitive enhancement is essential to inform policy and practice guidelines. AJOB Primary Research, 3: 58-60.
11. Lucke, J. C., Bell, S.Partridge, B. 2011a. Deflating the neuroenhancement bubble. AJOB Neuroscience, 2: 38-43.
12. Lucke, J. C., Bell, S. K.Partridge, B. J. 2011b. Academic doping or Viagra for the brain?. EMBO Reports, 12: 197-201.
13. Nadler, R. and Reiner, P. B. 2011. Prototypes or pragmatics? The open question of public attitudes toward enhancement. AJOBNeuroscience, 2: 49-50.
14. Partridge, B. 2010. Response. Journal of Bioethical Inquiry, 7: 385-386.
15. Partridge, B. J., Bell, S. K.Lucke, J. C. 2011. Smart drugs "as common as coffee": Media hype about neuroenhancement. PLoS ONE, 6: e28416
16. Savulescu, J., Foddy, B. and Clayton, M. 2004. Why we should allow performance enhancing drugs in sport. British Journal of Sports Medicine, 38: 666-670.
17. Smith, M. E. and Farah, M. J. 2011. Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychological Bulletin, 137: 717-741.